Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.58. Xtant Medical shares last traded at $0.51, with a volume of 56,212 shares traded.
Analyst Upgrades and Downgrades
Separately, Craig Hallum set a $1.50 price objective on Xtant Medical and gave the stock a "buy" rating in a research report on Friday, October 18th.
Check Out Our Latest Stock Report on Xtant Medical
Xtant Medical Price Performance
The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $70.20 million, a P/E ratio of -3.88 and a beta of 0.34.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The company had revenue of $27.94 million for the quarter.
Institutional Investors Weigh In On Xtant Medical
A hedge fund recently bought a new stake in Xtant Medical stock. Evernest Financial Advisors LLC acquired a new position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 40,000 shares of the medical device company's stock, valued at approximately $27,000. Hedge funds and other institutional investors own 69.33% of the company's stock.
Xtant Medical Company Profile
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
